Evommune, Inc. (EVMN) has received a new Buy rating, initiated by Morgan Stanley analyst, Judah Frommer.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Judah Frommer has given his Buy rating due to a combination of factors that highlight Evommune, Inc.’s promising future in the inflammatory and immunology (I&I) markets. The company is led by an experienced management team with a track record of successfully bringing anti-inflammatory therapies to market. Their current focus on developing treatments for chronic urticaria (CU) and atopic dermatitis (AD) addresses significant unmet needs in these areas, where there is a lack of safe oral treatment options for patients.
Frommer notes the strong mechanistic rationale behind Evommune’s lead candidates, EVO756 and EVO301, which could potentially revolutionize current treatment paradigms. EVO756, an MRGPRX2 inhibitor, is in advanced stages of development and shows promise as an early-line oral option for CU and AD, with potential peak sales reaching $1.3 billion by 2040. Meanwhile, EVO301, targeting IL-18, offers synergistic potential for the pipeline and has shown encouraging efficacy in AD, even in patients who have not responded to other treatments. With multiple catalysts expected in 2026, the risk/reward profile appears favorable, justifying the Buy rating.
Frommer covers the Healthcare sector, focusing on stocks such as Galapagos, Zenas BioPharma, Inc., and Incyte. According to TipRanks, Frommer has an average return of 1.5% and a 54.81% success rate on recommended stocks.